Third Harmonic Bio Announces Third Quarter 2024 Financial Results
Provided By GlobeNewswire
Last update: Nov 7, 2024
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25
Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024
Read more at globenewswire.com
